Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
GLP-1RA, Glucose Monitoring, Other, SGLT2i

Lilly to Acquire Versanis Bio; Brenzavvy Available by Prescription at Mark Cuban Cost Plus Drug Company; Abbott Initiates Libre 3 trial in T2DM and Basal Therapy; Nemaura FY ‘22 Earnings Update

Here is a brief preview of this blast: Four cardiometabolic-related news items have been observed: Lilly and Versanis Bio announced a definitive agreement for Lilly to acquire Versanis (view press release); TheracosBio announced Brenzavvy (bexagliflozin) is available by prescription through the Mark Cuban Cost Plus Drug Company (view press release); Abbott initiated a new trial evaluating its FreeStyle Libre 3 in adults with T2DM on basal therapy (view CT.gov record); and Nemaura Medical announced business updates and financial results for its FY ‘22 (view press release). Below, FENIX provides highlights and insights into the respective news items.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.